GenSight Biologics Past Earnings Performance
Past criteria checks 0/6
GenSight Biologics has been growing earnings at an average annual rate of 5.2%, while the Biotechs industry saw earnings growing at 17.7% annually. Revenues have been declining at an average rate of 4.3% per year.
Key information
5.2%
Earnings growth rate
21.0%
EPS growth rate
| Biotechs Industry Growth | 11.5% |
| Revenue growth rate | -4.3% |
| Return on equity | n/a |
| Net Margin | -884.6% |
| Next Earnings Update | 23 Jul 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How GenSight Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 3 | -26 | 13 | 19 |
| 30 Sep 23 | 3 | -28 | 14 | 20 |
| 30 Jun 23 | 3 | -29 | 15 | 21 |
| 31 Mar 23 | 4 | -28 | 14 | 20 |
| 31 Dec 22 | 5 | -28 | 13 | 19 |
| 30 Sep 22 | 5 | -29 | 14 | 22 |
| 30 Jun 22 | 5 | -31 | 14 | 25 |
| 31 Mar 22 | 6 | -30 | 13 | 24 |
| 31 Dec 21 | 8 | -29 | 13 | 23 |
| 30 Sep 21 | 9 | -28 | 12 | 21 |
| 30 Jun 21 | 11 | -28 | 11 | 18 |
| 31 Mar 21 | 9 | -31 | 10 | 20 |
| 31 Dec 20 | 7 | -34 | 10 | 22 |
| 30 Sep 20 | 7 | -31 | 9 | 23 |
| 30 Jun 20 | 6 | -28 | 8 | 25 |
| 31 Mar 20 | 5 | -30 | 7 | 27 |
| 31 Dec 19 | 5 | -31 | 6 | 29 |
| 30 Sep 19 | 5 | -35 | 7 | 32 |
| 30 Jun 19 | 5 | -39 | 8 | 36 |
| 31 Mar 19 | 5 | -36 | 8 | 32 |
| 31 Dec 18 | 4 | -33 | 8 | 29 |
| 30 Sep 18 | 4 | -30 | 8 | 25 |
| 30 Jun 18 | 4 | -26 | 8 | 21 |
| 31 Mar 18 | 4 | -25 | 9 | 20 |
| 31 Dec 17 | 4 | -24 | 9 | 19 |
| 30 Sep 17 | 3 | -23 | 9 | 18 |
| 30 Jun 17 | 3 | -23 | 9 | 17 |
| 31 Mar 17 | 3 | -22 | 8 | 17 |
| 31 Dec 16 | 3 | -22 | 7 | 18 |
| 30 Sep 16 | 3 | -20 | 6 | 16 |
| 30 Jun 16 | 4 | -18 | 5 | 14 |
| 31 Mar 16 | 4 | -16 | 5 | 12 |
| 31 Dec 15 | 4 | -14 | 4 | 10 |
| 30 Sep 15 | 3 | -11 | 3 | 9 |
| 30 Jun 15 | 2 | -9 | 3 | 9 |
| 31 Mar 15 | 2 | -8 | 2 | 7 |
| 31 Dec 14 | 1 | -7 | 2 | 6 |
| 31 Dec 13 | 1 | -3 | 1 | 3 |
Quality Earnings: 0RIM is currently unprofitable.
Growing Profit Margin: 0RIM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0RIM is unprofitable, but has reduced losses over the past 5 years at a rate of 5.2% per year.
Accelerating Growth: Unable to compare 0RIM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0RIM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.5%).
Return on Equity
High ROE: 0RIM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.